1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Advanced Proteome Therapeutics Corporation

Advanced Proteome Therapeutics Corporation

APTCF
Advanced Proteome Therapeutics CorporationUS flagOther OTC
0.00
USD
-NaN
- -
149,630.00Market Cap
Advanced Proteome Therapeutics Corporation
APTCF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
0.01
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.35
-0.17
-0.14
-0.16
-0.09
-0.1
-0.12
-0.12
-0.1
-0.06
-0.06
-0.05
-0.02
-0.02
-0.06
0.02
-0.05
Basic EPS, GAAP
-0.2
-0.17
-0.15
-0.13
-0.12
-0.07
-0.09
-0.09
-0.09
-0.07
-0.06
-0.08
-0.04
-0.02
-0.02
-0.02
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.92
-1.68
-1.75
-1.91
-1.94
-2
-1.87
-1.72
-1.62
-1.62
-0.14
-0.14
-0.12
-0.11
-0.1
-0.05
- -
Book Value per Share
0.27
0.35
0.19
0.05
0.02
-0.05
-0.08
-0.04
0.02
-0.04
-0.06
-0.06
-0.05
-0.06
-0.06
-0.02
- -
Tangible Book Value per Share
5
7
7
7
7
7
9
10
11
11
12
15
17
22
32
39
40
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-3,670.99
-1,532.5
-2,332.99
-13,209.91
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-1
-1
-1
-1
-1
-1
-1
-1
-1
-1
-1
- -
- -
-2
1
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-3,217.19
-1,201.84
-1,918.92
-13,296.6
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
2
1
- -
- -
- -
- -
- -
- -
- -
-1
- -
-1
-1
- -
-1
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
2
1
- -
- -
- -
-1
- -
- -
- -
-1
-1
-1
-1
-2
-1
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-22.87
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'23
Jan'23
Apr'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
41
41
Market Capitalization
4
4
2

Working Capital

FRC

•

in mil. unless spec.
Oct'23
Jan'23
Apr'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
- -
Payables & Accruals
1
1
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-32.01%
11.41%
-58.68%
Free Cash Flow
7.86%
7.31%
29.34%
Net Income, GAAP
16.14%
29.76%
-141.41%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.01
- -
-0.05
- -
-0.06
2022
0.02
0.02
-0.01
- -
0.02
2023
-0.01
-0.01
-0.04
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Stealth BioTherapeutics Corp (MITO)
Entera Bio Ltd. WT EXP 062723 (ENTXW)
Spago Nanomedical AB (publ) (SPAGO.ST)
Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
AIkido Pharma Inc. (AIKI)
Unity Biotechnology, Inc. (UNBX)
Business
Advanced Proteome Therapeutics Corporation (TSXV:APC, OTC:APTCF), through its subsidiary Advanced Proteome Therapeutics Inc., operates as a biotechnology company focused on developing proprietary site-selective protein modification technologies to produce superior antibody-drug conjugates (ADCs) for targeted cancer treatment; the platform simplifies and standardizes ADC manufacturing by enabling precise chemical modification of antibodies, control of drug-antibody ratios, and combination payloads, resulting in greater potency, higher specificity, and lower toxicity compared to conventional therapies; core offerings include protein conjugation technologies for oncology applications, such as streamlining production of agents that deliver anti-cancer drugs directly to tumors while sparing healthy cells. The company targets the oncology sector, serving pharmaceutical partners seeking advanced ADC solutions, and maintains operations in North America with laboratory facilities at Boston University BioSquare in Boston, Massachusetts, USA, and corporate headquarters at 8337 Eastlake Drive, Suite 104, Burnaby, British Columbia, Canada V5A 4W2; founded in 2005, it pursues dual paths of licensing its platform technology and developing proprietary therapeutics. Recent developments include the appointment of Dr. Benjamin Krantz as President and CEO in July 2021, expansion of lab space for mammalian cell culture and hiring of an organic chemist in 2022 to accelerate ADC validation, and ongoing collaborations such as with Heidelberg Pharma to combine site-selective modification with amanitin-based toxins, yielding positive preclinical animal study results in 2022; the company continues advancing these partnerships and internal projects toward clinical candidates and licensing opportunities.